Brigatinib in japanese patients with tyrosine kinase inhibitor-naive alk-positive non-small cell lung cancer: first results from the phase 2 j-alta study

HIGHLIGHTS

• who: Shunichi Sugawara from the (UNIVERSITY) have published the research: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study, in the Journal: (JOURNAL) of September/29,/2020
• what: The authors report here the results from the TKI-naive cohort of J-ALTA. no previous TKI therapy (Fig 1).
• how: The authors evaluated the safety and efficacy of the anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) brigatinib in Japanese patients with TKI-naive ALK-positive non-small . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.